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Brief Communication
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The demand for liver transplantation (LT) exceeds
supply, with rising waiting list mortality. Utilization of
high-risk organs is low and a substantial number of
procured livers are discarded. We report the first ser-
ies of five transplants with rejected livers following
viability assessment by normothermic machine perfu-
sion of the liver (NMP-L). The evaluation protocol con-
sisted of perfusate lactate, bile production, vascular
flows, and liver appearance. All livers were exposed to
a variable period of static cold storage prior to com-
mencing NMP-L. Four organs were recovered from
donors after circulatory death and rejected due to pro-
longed donor warm ischemic times; one liver from a
brain-death donor was declined for high liver function
tests (LFTs). The median (range) total graft preserva-
tion time was 798 (range 724–951) min. The transplant
procedure was uneventful in every recipient, with
immediate function in all grafts. The median in-
hospital stay was 10 (range 6–14) days. At present, all
recipients are well, with normalized LFTs at median
follow-up of 7 (range 6–19) months. Viability assess-
ment of high-risk grafts using NMP-L provides specific
information on liver function and can permit their
transplantation while minimizing the recipient risk of
primary graft nonfunction. This novel approach may
increase organ availability for LT.
Abbreviations: ALT, alanine transaminase; CIT, cold
ischemic time; DBD, donor/donation after brain
death; DCD, donor/donation after circulatory death;
dWIT, donor warm ischemic time; ld, large droplet;
ITU, intensive therapy unit; LFTs, liver function tests;
LT, liver transplantation; MS, macrovesicular steato-
sis; NHS, National Health Service; NMP-L, normoth-
ermic machine perfusion of the liver; SCS, static cold
storage; sd, small droplet
Received 04 February 2016, revised and accepted for
publication 28 April 2016
Introduction
Deaths from liver disease have soared by 40% in the last
decade, killing 11 000 a year in England at an average age
of 59 years (1). Liver transplantation (LT) is highly success-
ful in treating end-stage disease, but access is restricted
by the number of available organs and approximately 20%
of patients die while awaiting transplantation (2–5). To
address this, more transplants are performed using high-risk
organs, from donors with comorbidities or relative con-
traindications (6–9). These organs, termed “marginal” or
“extended criteria” grafts, are more susceptible to cold
ischemia, and have an increased risk of graft failure, and
recipient morbidity and mortality (7,10). The devastating con-
sequences of graft failure following LT preclude greater uti-
lization of high-risk livers. For example, in 2014–2015, of
1282 identified UK donors, only 924 (72%) livers were
deemed suitable for retrieval and 812 (63%) were subse-
quently transplanted (2). Data from the United States are
similar, and the latest report of the Organ Procurement and
Transplant Network showed that only 6312 out of 8144
(78%) potential donor livers were transplanted (3). Over the
same period, in these two countries combined more than
3200 patients died or were removed from the transplant
waiting list for being too sick for transplantation (3,11).
Normothermic machine perfusion of the liver (NMP-L) is
a novel technique, substituting the detrimental effect of
static cold storage (SCS) by preserving the organs in
near-physiological conditions, with oxygen and nutrients
1
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at 37°C. The preserved metabolic activity at normother-
mia not only prevents further graft damage caused by
ischemia, but allows ex-situ monitoring of liver function
by permitting objective assessment of liver biochemistry,
blood flow, and bile production. The complexity of dual—
arterial and portal—liver inflow has proved technically
challenging. The first machine introduced into clinical
practice was recently developed by the Oxford group,
and was used for the pilot liver transplant series using
standard criteria organs preserved by NMP-L, completely
avoiding SCS (12). Our preclinical studies on discarded
livers showed that perfusate lactate clearance in combi-
nation with bile production and stable blood flow rates
are sensitive parameters predictive of graft viability, and
in August 2014 our group carried out the first-in-human
transplant of such a liver graft (13,14). Here, we present
the first five recipients of NMP-L-treated rejected liver
allografts.
Methods
Study design
This series evolved from a research project of viability testing of rejected
human livers where NMP-L-based viability criteria were established and a
perfusion fluid was developed to facilitate resuscitation of high-risk
organs. After defining viability criteria, we obtained approval from the
hospital ethics and novel therapeutic committees in June 2014 to per-
form a pilot series of five clinical transplants. Here we present the results
of six consecutive NMP-Ls, commenced with an intention to perform
clinical transplantation in carefully selected and consented adults with
grafts that met viability criteria.
Source of rejected human livers
Based on donor history and laboratory results, the livers (except donor 4
with progressively rising liver function tests [LFTs]) were initially accepted
and procured by one of the teams from the UK National Organ Retrieval
Service, using a nationally agreed surgical protocol, with the intention of
transplantation (15). All grafts were initially preserved in University of
Wisconsin preservation fluid at 4°C.
On arrival at the transplanting center, each liver was assessed and
deemed unsuitable by the consultant surgeon. The liver was then offered
to and turned down by all UK liver transplant centers and then offered for
use in our pilot study by the National Health Service Blood and Transplant
(NHSBT) coordinating office. Ethical approval for the study was granted
by the University Hospital Birmingham NHS Foundation Trust Novel Ther-
apeutics and NHSBT Ethics Committees.
To ensure safety, risks were minimized by excluding livers with a signifi-
cant pre-existing disease, and all grafts in this study met the following
inclusion criteria: cold ischemic times (CIT) less than 16 h for livers from
donors after brain death (DBD), or less than 10 h from donors after circu-
latory death (DCD), donor warm ischemic time (dWIT; defined as the
interval between systolic blood pressure less than 50 mmHg or oxygen
saturation less than 70% to aortic perfusion) in DCD organs less than
60 min, absence of hepatitis B, hepatitis C, or human immunodeficiency
virus infection, and a macroscopic appearance without fibrosis or cirrho-
sis. Following a review of the protocol after the unsuccessful second per-
fusion, an additional criterion of maximum donor age of 65 years was
added.
We were offered about 15 livers for machine perfusion research over the
study period but utilized only a proportion of these due to the limited
availability of personnel to perform the perfusions.
Clinical protocol for liver viability testing
Graft preparation was analogous to the standard back-table procedure,
and the portal vein was dissected and cannulated. The celiac trunk
branches were ligated and the hepatic artery was dissected to the gastro-
duodenal artery. We routinely attached an iliac artery interposition graft to
the aortic patch to facilitate the insertion of the arterial perfusion cannula.
The perfusion fluid was based on 3 units of the donor liver specific blood
group, Rhesus-negative, packed red blood cells, supplemented with
1000 mL human albumin solution 5%, 30 mL sodium bicarbonate 8.4%,
and 10 mL calcium gluconate 10%. The circuit was loaded with 10 000 IU
heparin, 500 mg vancomycin, and 60 mg gentamicin prior to connecting
the liver, with the continuous infusion of epoprostenol (8 lg/h).
NMP-L was then commenced, using two different devices. Livers from
donors 1 to 5 were perfused with Liver Assist (Organ Assist, Groningen,
the Netherlands). This device provides a pulsatile arterial and continuous
nonpulsatile portal flow via two independent rotary pump circuits. The liver
from donor 6 was perfused with the OrganOx Metra device (OrganOx,
Oxford, UK) delivering continuous nonpulsatile arterial and portal flows
powered by one rotary pump. Organ viability was assessed within 3 h of
perfusion. In a viable liver the perfusate lactate level had to be less
than 2.5 mmol/L or the liver had to produce bile, in combination with at
least two of the following three criteria: (1) perfusate pH greater than 7.30,
(2) stable arterial flow of more than 150 mL and portal venous flow more
than 500 mL per min, and (3) homogeneous graft perfusion with soft con-
sistency of the parenchyma.
Histology
Menghini liver biopsies were obtained at three time points: (1) pre-NMP-L,
(2) at the end of NMP-L, and (3) following reperfusion of the implanted liver.
The cut end of the common bile duct was obtained post-NMP-L. All biop-
sies were placed in 10% formalin and processed by standard procedures to
a paraffin block. Sections stained with hematoxylin and eosin and periodic
acid–Schiff were examined for the percentage of large droplet (ld) and small
droplet (sd) macrovesicular steatosis (MS), hepatocyte necrosis, and glyco-
gen depletion. Preservation–reperfusion injury in postreperfusion biopsies
was graded based on these features together with neutrophil infiltration.
The grading system used has been developed in-house over many years by
correlation with peak postoperative transaminases (unpublished data) and
evolved from examination of sequential findings prior to retrieval, during
cold storage, and following reperfusion (16). Bile duct biopsies were
assessed for loss of the lining epithelium, epithelial damage in superficial
and deep peribiliary glands, stromal necrosis, arteriolar necrosis, and throm-
bosis according to previously published criteria (17). Histological assess-
ments were all performed after graft implantation and therefore did not
impact on decisions concerning viability assessment.
Transplant recipients
The recipients were patients listed for transplantation at Queen Elizabeth
Hospital Birmingham, UK. All patients received an explanation about the
principles of NMP-L during consenting for LT. When a recovered viable
liver graft became available, the consultant surgeon familiar with the pro-
ject re-explained the procedure in detail and obtained patients’ additional
consent to accept the graft. Recipients considered for this study had low
surgical perioperative risk as assessed by the multidisciplinary team dur-
ing the listing process. Patients with hepatocellular carcinoma, with a
high risk of waiting list dropout due to tumor progression, were regarded
as favorable recipients.
2 American Journal of Transplantation 2016; XX: 1–11
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LT procedure and patient follow-up
The grafts were implanted with the vena cava–preserving technique. After
completing the native liver hepatectomy, the NMP-L was stopped and
the graft was flushed with 2 L of cold histidine–tryptophan–ketoglutarate
solution, vascular and bile duct cannulas were removed, and bile duct
and liver biopsies were taken. The graft was immediately implanted and
reperfused in the standard manner. The perioperative data, posttransplant
laboratory results, and details of the patient’s recovery course were col-
lected. Following discharge from the hospital, patients were reviewed in
the outpatient clinic with weekly (first month) and then every 2 weeks
(second to third month) frequency.
Results
The median donor age was 49 (range 29–54) years. Four
livers were recovered from DCD and two from DBD
donors. There was an even split between the liver offers
initially accepted and retrieved by our team versus other
teams. The median CIT was 422 (387–474) min. Five out
of six livers met the viability criteria and were used for
transplantation. The detailed demographics and graft
characteristics are provided in Table 1.
Donor history details and reasons for initial graft
rejection
Donor 1 (DCD) was a 29-year-old diabetic male admitted
with cardiac arrest, having elevated LFTs. The dWIT was
109 min and the graft appearance was patchy. The liver
was rejected due to prolonged dWIT and poor perfusion.
Donor 2 (DBD) was a 69-year-old male ventilated for
27 days following surgery for ascending aorta dissection,
with a peak alanine transaminase (ALT) of 2264 IU/L and
multiple cardiac arrests. The liver was rejected based on
history and LFTs.
Donor 3 (DCD) was a 49-year-old female with BMI
45 kg/m2 with a history of hypertension, depression with
two suicide attempts with paracetamol overdose, and
deep vein thrombosis with an infected chronic leg ulcer.
The liver was rejected due to the prolonged dWIT
(36 min) in combination with high BMI.
Donor 4 (DBD) was a 54-year-old female with an intracra-
nial bleed postresection of a suprasellar meningioma.
Because of rising LFTs (ALT 997 IU/L on day of dona-
tion), the liver was not accepted.
Donor 5 (DCD) was a 46-year-old male who collapsed with a
cardiac arrest of 40-min duration. He was a known heavy drin-
ker and the admission ALT was 1297 IU/L. The graft was
rejected due to its large size (2486 g) and abnormal LFTs.
Donor 6 (DCD) was a 51-year-old male with an intracranial
hemorrhage, diabetes on metformin, and BMI 33 kg/m2.
The liver was rejected due to large size (2522 g) and stea-
totic appearance on macroscopic assessment.
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Viability evaluation
All but one liver met defined criteria for viability and
showed signs of function as assessed by the perfusate
lactate clearance and bile production. The median start-
ing lactate level was 9.9 mmol/L that decreased in 2 h to
the median level 1.5 mmol/L (Figure 1A). The median
NMP-L time was 332 (318–564) min. The total preserva-
tion time of the transplanted livers was 798 (724–
951) min.
The donor 2 liver did not meet viability criteria, despite
initially showing a rapid lactate clearance with levels
decreasing from 11.4 to 2.1 mmol/L within the first 2 h
of perfusion. The liver had aberrant arterial anatomy, with
an accessory right hepatic artery rising from the superior
mesenteric artery. Despite a presence of back-flow
bleeding from the artery stump after graft connection to
the device, there was noticeable color difference on the
liver surface after 90 min of perfusion, prompting arterial
reconstruction. Following re-established inflow via the
accessory artery, lactate levels rose and did not normal-
ize within the 3-h time frame, and the liver was
discarded. This event suggests that any vascular recon-
struction for aberrant arterial anatomy should be per-
formed prior to commencing the perfusion.
The donor 6 graft function recovery occurred soon after
starting NMP-L, with fluctuations and increase of lactate
levels during the later perfusion course. In terms of the
decision-making, we consider the key lactate reading as
being the one taken at the time of graft viability assess-
ment (the point when lactate drops below 2.5 mmol/L,
or the reading taken at 3 h after commencing NMP-L).
Although we continued to measure the parameters every
30 min thereafter, these values do not have any impact
on the transplantation procedure, as the recipient opera-
tion is already in progress. Details of the NMP-L parame-
ters, graft function, and transplantation procedure are
provided in Table 1.
Histological findings
No significant ld steatosis was seen in these livers,
with the majority (four of six) also having negligible
sdMS and two having mild (<33%) sdMS (Figures 2A
and B). Hepatocyte necrosis (Figures 2C and D) of more
than just a few cells was present in one liver that was
transplanted (30% increasing to 50% posttransplant),
and in the one that did not reach transplant criteria
(15% hepatocyte loss from necrosis at an earlier time
point). In four of five of the transplanted livers, glycogen
stores appeared to be replenished during NMP-L (Fig-
ures 2E and F). The injury posttransplant varied from
mild to severe.
Bile duct injury (Figure 3) was generally mild: there were
only mild epithelial changes in deep peribiliary glands in
the livers transplanted. One post-NMP-L bile duct biopsy
showed mild, two moderate, and three severe stromal
Figure 1: Viability assessment by the perfusate lactate
clearance and the posttransplant liver function tests.
Panel (A) shows the lactate clearance during the normothermic
perfusion. All livers demonstrated metabolic activity, and per-
fusate lactate levels dropped below 3.0 mmol/L. In liver number
2 the lactate levels fell to 2.1 mmol/L, but started to rise again
after 150 min. The organ failed to meet the viability criteria and
was not used for transplantation. Panel (B) shows the posttrans-
plant changes in the ALT levels; the enzyme is often used as a
surrogate marker for preservation-related liver injury. The initial
posttransplant levels were similar in all livers, with progressive
improvement within the first posttransplant week. In all recipi-
ents the ALT levels were normal within the first month after
transplantation. Panel (C) demonstrates a similar improvement
pattern with bilirubin levels. In recipient number 1, bilirubin
levels slightly increased later during follow-up and the magnetic
cholangiography performed at 6 months posttransplant revealed
a mild anastomotic biliary stricture. The bilirubin level normalized
with conservative management of ursodeoxycholic acid medica-
tion. ALT, alanine transaminase.
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nuclear loss. Mild arteriolar necrosis was seen in three of
the post-NMP-L biopsies. Thrombosis was not seen. The
detailed findings are provided in Table 2.
Patient outcomes
The median recipient age was 56 (range 47–66) years.
The transplantation procedure was uneventful for every
recipient, with immediate function recovery in all grafts.
The median intensive therapy unit (ITU) stay was 3
(range 2–6) days, with one early ITU readmission in a
patient who developed acute coronary syndrome 8 days
following surgery, requiring percutaneous coronary inter-
vention with stent insertion. The median in-hospital stay
was 10 (range 6–15) days. To date, all patients are well,
with normalized liver tests at a median follow-up of 7
(range 6–19) months. Recipient 3 (donor 4 liver) showed
a different posttransplant ALT profile compared to the
other recipients, and this may be related to the severe
preretrieval injury as documented by the progressively
rising ALT (peak 997 IU/L) within 24 h prior to donation
A B
C D
E F
Figure 2: Histological findings in liver biopsies. Panels (A) and (B) show pre-NMP-L H&E-stained biopsies from liver number 5.
Panel (A) shows negligible large droplet macrovesicular steatosis (109 objective). Panel (B) is a higher magnification showing small
droplet macrovesicular steatosis involving roughly 20–30% of the hepatocytes. This is seen within the circled area as tiny white holes
in the hepatocytes. This type of steatosis, often referred to as microvesicular steatosis, is not considered to be important in determin-
ing the amount of fat in an assessment for transplantation. None of the livers had more than 5% large droplet steatosis, the type that
determines suitability for transplantation (209 objective). Panels (C) and (D) demonstrate areas of necrosis seen as the pale pink hepa-
tocytes (arrows) in post-NMP-L biopsies from liver number 5. Panel (C) shows approximately 30% necrosis in the preimplantation
biopsy. Panel (D) shows an increase in the number of necrotic hepatocytes in the postreperfusion biopsy, approximating to 50% of
the liver parenchyma. This liver showed the most necrosis in this presented series; this degree of necrosis is considered unfavorable
by currently used assessment standards. The additional information provided by the functional assessment using the normothermic
perfusion confirmed the liver viability and the graft was successfully transplanted with immediate intraoperative recovery of the func-
tion and good patient recovery (both sections H&E, 109 objective). Panels (E) and (F) are PAS-stained sections of biopsies from liver
number 1 in which glycogen in hepatocytes stains dark pink. Panel (E) shows the pre-NMP-L biopsy with moderate glycogen deple-
tion. Panel (F) shows the post-NMP-L biopsy with increased glycogen content, now amounting to only mild depletion (both 109 objec-
tive). H&E, hematoxylin and eosin; NMP-L, normothermic machine perfusion of the liver; PAS, periodic acid–Schiff.
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(Figures 1B and C). This might also explain the different
pattern of its lactate clearance, and in this particular case
the viability criteria were met by bile production rather
than lactate level at 3 h.
The recipient demographics and outcome details are pro-
vided in Table 3.
Discussion
The consequences of transplanting a liver that fails to
function are potentially dire. NMP-L offers the opportu-
nity to assess and improve the quality of high-risk livers
deemed unsuitable for transplantation. To our knowl-
edge, this report describes the first patient series of “re-
jected” liver allografts transplanted following successful
assessment and resuscitation by NMP-L. This pilot study
shows that a proportion of high-risk donor livers might
be transplanted by subjecting them to viability testing
during NMP-L, without compromising patient safety in a
cohort of low-risk recipients.
Since transplantation was established as a highly suc-
cessful treatment almost half a century ago, scarcity of
suitable donors has become a worldwide factor limiting
access to this treatment. Ongoing advancements, rang-
ing from the improved management of intracranial vascu-
lar malformations to the vast improvements in road
traffic safety, have had an impact on decreasing the
availability of DBD organ donors. National and interna-
tional regulatory bodies have proposed strategies and
identified funding to overcome the shortage, but these
are largely based on increasing the number of extended
criteria organs, known to be associated with a higher risk
for the recipient (18).
Machine perfusion technology has shown promising
results in preserving cardiothoracic and abdominal organs
(12,19–23). Although most of the reported series showed
its feasibility in organs acceptable for transplantation, the
technology has already demonstrated the potential to
expand the donor pool. For example, the team at St Vin-
cent’s Hospital in Sydney recently reported a series of
heart transplants using allografts recovered from donors
after circulatory death that were previously deemed
unfeasible (20).
Normothermic perfusion replicating near-physiological con-
ditions ex-vivo has for a long time been regarded as the
optimal machine perfusion strategy, but has required
advanced technology that was previously not available. Sev-
eral groups have successfully pursued simpler hypothermic
machine perfusion (HMP) (21,24,25). The early adoption of
HMP was also facilitated by the negligible risk of graft loss
related to potential device malfunction. Clinical trials of
HMP of kidneys have demonstrated improved results in
renal transplantation (23,26). Numerous teams have
A
B
C
Figure 3: Bile duct histology. This figure demonstrates H&E-
stained sections of bile duct. The double arrowhead shows the
surface epithelial lining and the single arrowhead points to a
deep peribiliary plexus. Panel (A) shows the surface epithelium
is intact in this part of the bile duct with relatively mild changes
to the deep peribiliary glands in liver number 6. Panel (B) dis-
plays partial surface epithelial loss with well-preserved peribiliary
glands in liver 4. Panel (C) shows another fragment of bile duct
from liver 6 in which there is moderately extensive loss of sur-
face epithelium, with stromal nuclear loss deep to the double
arrowhead; the deep peribiliary glands in this area look moder-
ately injured (all 109 objective). H&E, hematoxylin and eosin.
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reported encouraging outcomes following HMP of the liver;
however, the first reported high-risk graft series demon-
strated a high incidence of biliary complications and also pri-
mary nonfunction was observed (21,27).
The devastating consequences of primary graft nonfunc-
tion in cardiothoracic transplantation and LT preclude fur-
ther extension of organ acceptance criteria. The utilization
of high-risk hearts or lungs is only 30–40%, which might
relate to the use of ventricular assist devices and extracor-
poreal membrane oxygenation as a bridge to transplanta-
tion until a lower-risk donor becomes available. In contrast,
the constant growth in demand for liver transplants has
extended utilization of marginal livers to 70–80%, often
compromising posttransplant outcomes and patients’
safety (7,10).
The limits in the utilization of high-risk livers have been
explored in countries such as the United Kingdom, where
these organs can be allocated to lower-risk recipients
(28,29). The protocol presented here may transform use
of high-risk livers. Diminishing the risk of primary non-
function or severe dysfunction, with their often fatal con-
sequences, might allow further evolution of this novel
approach and permit safe allocation of high-risk organs to
the sickest recipients, benefiting the patients with the
highest waiting list mortality (30).
In this series, the livers were declined by all the UK
transplant units and NMP-L was commenced following a
variable period of static cold storage, with no differences
observed between the use of the two available devices,
and five out of six tested grafts were viable. During the
period of this pilot study, there were 149 (81 DCD, 68
DBD) livers meeting the study inclusion criteria discarded
in the United Kingdom. Recovering 70% of these organs
would allow over 100 additional LTs in the United King-
dom, increasing the number of available organs by 15%
(unpublished data, courtesy of Sally Rushton, NHSBT).
We envisage that viability testing will transform the
organ selection and acceptance process, and this case
series represents a promising start. The technique
showed favorable outcomes in a predefined subgroup of
high-risk organs. Nevertheless, the presented results
must be taken cautiously and seen as a feasibility report.
One limitation is that this small group of livers did not
include any organs with moderate or severe ld fatty
change (macrosteatosis), a key risk factor for initial graft
dysfunction/primary nonfunction. Other potential limita-
tions could be the additional costs and challenges of
wider implementation of NMP-L technology and exper-
tise, but this may be justified by the increases in trans-
plant activity and improved organ utilization. In addition,
our study shows the feasibility of performing NMP-L fol-
lowing SCS and inspection at the transplant center, with
logistical and financial advantages, and may allow target-
ing of livers that would benefit most from NMP-L.
This report demonstrates that a proportion of currently
rejected livers might be salvaged by subjecting them to
NMP-L and viability testing. Use of this technology may
transform the utilization of high-risk organs and improve
access for patients to transplantation.
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